acut
respiratori
distress
syndrom
ard
devast
disord
character
overwhelm
pulmonari
inflamm
lead
hypoxemia
respiratori
failur
ard
sever
categor
mild
mm
hg
pao
fio
mm
hg
moder
mm
hg
pao
fio
mm
hg
sever
pao
fio
mm
hg
approxim
patient
admit
intens
care
unit
icu
diagnos
ard
accord
berlin
definit
repres
nearli
million
patient
ard
global
per
annum
differ
classif
berlin
definit
recent
studi
suggest
ard
stratifi
two
biolog
phenotyp
hypoinflammatori
hyperinflammatori
also
refer
reactiv
hyperinflammatori
phenotyp
sever
clinic
featur
respond
rang
treatment
includ
peep
fluid
manag
pharmacotherapi
despit
signific
insight
pathophysiolog
ard
establish
patient
mortal
high
evidencebas
therapeut
option
limit
mechan
ventil
support
adequ
ga
exchang
lifesav
intervent
critic
ill
patient
respiratori
failur
unfortun
mechan
ventil
also
contribut
lung
injuri
via
process
known
ventilatorinduc
lung
injuri
vili
also
term
ventilatorassoci
lung
injuri
vali
preval
among
mechan
ventil
patient
histor
applic
potenti
injuri
mechan
ventil
use
larg
tidal
volum
v
high
peak
airway
pressur
p
peak
increas
risk
develop
ard
icu
odd
ratio
v
ml
p
peak
cm
surgic
ventil
odd
ratio
mlkg
increas
intraop
v
vili
character
inflammatori
cell
infiltr
lung
loss
epitheli
endotheli
integr
increas
capillari
permeabl
deposit
extracellular
matrix
interstiti
pulmonari
edema
fibrosi
improv
clinic
relev
twohit
model
lp
challeng
intratrach
intraperiton
follow
injuri
ventil
appli
preclin
studi
mimic
preexist
sepsi
common
caus
ard
vili
occur
previous
normal
lung
worsen
preexist
ard
occur
via
rang
mechan
includ
tissu
stress
caus
overdistens
lung
alveoli
expos
increas
transpulmonari
pressur
barovolutrauma
caus
high
local
shear
forc
atelectrauma
mechan
respons
trigger
recruit
leukocyt
releas
chemokinescytokin
lead
pulmonari
system
inflammatori
respons
biotrauma
accordingli
variou
artifici
ventil
strategi
small
v
avoid
lung
alveoli
overdistens
well
higher
posit
endexpiratori
pressur
peep
end
expir
employ
minim
impact
injuri
ventil
howev
improv
patient
outcom
recent
decad
pharmacolog
therapi
develop
shown
benefici
largescal
random
control
clinic
trial
rct
howev
recent
studi
suggest
role
reninangiotensin
system
ra
ard
vili
ra
well
known
primari
role
control
salt
retent
blood
pressur
role
inflamm
injuri
suggest
may
novel
therapeut
option
treatment
ard
vili
present
review
highlight
role
angiotensinii
angii
ra
compon
inflamm
injuri
associ
vili
renin
releas
juxtaglomerular
cell
kidney
cleav
macroglobulin
precursor
angiotensinogen
inact
decapeptid
angiotensini
angi
angi
enter
circul
transform
activ
octapeptid
angii
enzymat
cleavag
angiotensin
convert
enzym
ace
distribut
system
local
angii
act
promin
mediat
ra
bind
angiotensin
type
receptor
type
receptor
furthermor
angii
cleav
angiotensin
convert
enzym
form
angiotensin
ang
bind
ma
receptor
masr
antagon
effect
case
consider
interest
balanc
axi
masr
axi
blood
pressur
homeostasi
cardiovascular
function
shown
interestingli
normal
induc
activ
masr
axi
recent
evid
suggest
ang
may
activ
antagon
effect
addit
system
ra
local
express
almost
ra
compon
lung
major
sourc
ace
therefor
major
site
system
ang
ii
synthesi
metzger
colleagu
found
ace
express
abundantli
capillari
endotheli
cell
entir
capillari
network
alveoli
human
lung
result
pulmonari
vasoconstrict
occur
readili
respons
hypoxia
essenti
ventilationperfus
match
contrast
wiener
colleagu
found
primarili
locat
clara
cell
type
ii
alveolar
epitheli
cell
murin
lung
pulmonari
appear
role
regul
ang
iiang
level
recent
studi
shown
local
ra
compon
distribut
lungresid
immun
inflammatori
cell
thu
potenti
ra
system
rang
effect
context
lung
injuri
relat
vili
ard
aceangii
express
markedli
increas
patient
ard
patient
sepsi
common
caus
ard
clinic
epidemiolog
studi
shown
signific
associ
polymorph
ace
gene
suscept
ard
exampl
marshal
colleagu
found
ace
id
genotyp
frequenc
ace
ii
polymorph
increas
among
patient
ard
compar
control
homozyg
allel
confer
higher
level
ace
angii
tissu
serum
upregul
ace
activ
broadli
associ
rang
ard
relat
condit
includ
pneumonia
aspir
trauma
pancreat
notabl
mechan
ventil
wostenvan
asperen
colleagu
show
mechan
ventil
upregul
ace
activ
result
increas
convers
angi
angii
addit
respiratori
insult
caus
mark
increas
express
potenti
downstream
effect
activ
ace
angii
signal
exampl
jerng
colleagu
found
express
measur
rna
protein
level
increas
activ
aceangii
follow
injuri
ventil
experiment
model
vili
mediat
downstream
nuclear
transloc
cytosol
fraction
strongli
link
inflamm
number
studi
shown
angii
critic
mediat
inflammatori
cascad
alveolar
epitheli
injuri
associ
ard
exampl
angii
induc
dosedepend
apoptosi
human
rat
alveolar
epitheli
cell
aec
interact
number
differ
signal
pathway
involv
induct
apoptosi
aec
wang
colleagu
found
activ
prooxid
signal
superoxid
product
pathway
contribut
hyperoxiainduc
lung
injuri
fibrosi
li
colleagu
found
pathway
caus
activ
pathway
induc
apoptosi
aec
respons
seawat
inhalationinduc
lung
injuri
similarli
high
level
may
also
activ
secret
proinflammatori
cytokin
promot
macrophag
neutrophil
chemotaxi
contribut
vili
instanc
jiang
colleagu
found
angii
level
lung
correl
posit
macrophag
inflammatori
level
bronchoalveolar
lavag
fluid
balf
rodent
model
vili
critic
necessari
induct
apoptosi
aec
axi
respons
like
driven
activ
pathway
wherebi
activ
sepsisinduc
ard
associ
increas
angii
lead
phosphoryl
lead
product
proinflammatori
cytokin
deleteri
role
axi
activ
support
protect
effect
ace
inhibitor
experiment
studi
sever
independ
research
group
show
ace
inhibitor
angiotensin
receptor
blocker
arb
attenu
lung
edema
lung
aec
apoptosi
microvascular
permeabl
caus
ard
exampl
liu
colleagu
found
losartan
arb
attenu
neutrophilia
lpsinduc
respiratori
inflamm
mice
associ
inhibit
dendrit
cell
matur
suppress
immun
respons
line
anoth
studi
found
losartan
attenu
lung
injuri
induc
aec
apoptosi
ro
gener
observ
like
due
inhibit
activ
phosphoryl
similar
observ
report
model
vili
respons
ace
inhibitor
captopril
howev
experiment
model
use
arb
ace
inhibitor
promis
strong
evid
clinic
studi
associ
use
arb
ace
inhibitor
outcom
ard
vili
still
lack
especi
high
qualiti
rct
see
tabl
normal
express
low
level
lung
epitheli
cell
endotheli
cell
fibroblast
activ
myofibroblast
healthi
adult
howev
pulmonari
well
abundantli
upregul
chronic
lung
diseas
chronic
obstruct
pulmonari
diseas
copd
well
idiopath
pulmonari
fibrosi
ipf
exampl
shown
studi
jerng
colleagu
lung
tissu
mrna
well
angii
mrna
level
markedli
increas
highvolum
ventil
rat
often
similar
increas
ard
vili
oppos
promot
injuri
fibrosi
line
studi
imai
colleagu
show
mice
sever
patholog
respons
acid
aspir
induc
lung
injuri
wildtyp
control
number
benefici
action
lung
injuri
recent
demonstr
bruce
colleagu
found
treatment
nonpeptid
agonist
amelior
pulmonari
fibrosi
prevent
right
ventricular
fibrosi
pulmonari
hypertens
benefici
effect
abolish
coadministr
antagonist
furthermor
rathinasabapathi
colleagu
found
stimul
attenu
bleomycininduc
lung
injuri
allevi
lung
inflamm
fibrosi
doubleblind
placebocontrol
phase
iia
studi
approv
european
union
clinic
trial
regist
eudract
number
begun
evalu
effect
fibrot
lung
injuri
safeti
homologu
ace
cleav
singl
residu
angii
gener
ang
thu
act
neg
regul
ra
inactiv
angii
origin
identifi
potenti
receptor
sar
corona
viru
lung
express
also
shown
suppress
ard
exampl
acid
aspirationinduc
lung
injuri
associ
markedli
reduc
protein
express
elev
angii
level
decreas
activ
concomit
enhanc
ace
activ
occur
respons
lpsinduc
lung
injuri
import
ard
confirm
knockout
mous
model
wherebi
inhibit
express
result
enhanc
vascular
permeabl
increas
lung
edema
sever
inflammatori
cell
infiltr
impair
lung
function
supplement
recombin
abl
improv
outcom
measur
confirm
patholog
ard
character
inflammatori
cell
infiltr
lung
loss
epitheli
endotheli
integr
increas
capillari
permeabl
interstiti
pulmonari
edema
fibrosi
angii
locat
core
posit
ra
origin
upstream
angi
ace
sinc
ace
express
abundantli
entir
pulmonari
capillari
network
consider
amount
angii
enter
lung
alveoli
ard
occur
angii
combin
express
aec
inflammatori
cell
alveoli
exert
oppos
effect
overal
angii
promot
inflammatori
cell
activ
recruit
induc
pulmonari
aec
pvmec
apoptosi
lead
increas
microvascular
permeabl
loss
epitheli
endotheli
integr
convers
activ
function
attenu
inflamm
improv
aec
pvmec
surviv
reduc
lung
fibrosi
collagen
accumul
result
improv
lung
function
oxygen
besid
angii
metabol
downstream
ang
angiotensin
combin
masr
antagon
effect
thu
function
similar
play
benefici
role
lung
injuri
potenti
ard
partial
block
signal
benefici
role
mediat
ard
primarili
attribut
activ
ang
masr
signal
pathway
confirm
number
studi
supplement
ang
allevi
lung
edema
myeloperoxidas
activ
lung
injuri
pulmonari
vascular
resist
mous
model
ard
furthermor
chen
colleagu
found
treatment
ang
attenu
lung
fibrosi
collagen
deposit
lpsinduc
lung
injuri
suppress
signal
blockad
masr
larg
prevent
protect
effect
ang
demonstr
import
downstream
activ
pathway
mechan
benefici
effect
outcom
model
includ
inhibit
apoptosi
aec
pulmonari
microvascular
endotheli
cell
pvmec
well
reduct
prolifer
migrat
lung
fibroblast
instanc
studi
ang
masr
enhanc
surviv
aec
normal
show
excess
apoptosi
ard
gopallawa
colleagu
found
ang
masr
enhanc
mitogenactiv
protein
kinas
drive
apoptosi
aec
similar
effect
shown
pvmec
wherebi
activ
masr
axi
reduc
apoptosi
cytokin
secret
pmvec
inhibit
phosphoryl
jnknfkb
could
restor
masr
blockad
pharmacolog
manipul
masr
axi
level
shown
exert
protect
effect
variou
experiment
model
ard
see
tabl
specif
supplement
recombin
human
angiotensinconvert
enzym
ang
reduc
lung
injuri
convers
inhibit
masr
aggrav
ard
base
encourag
data
experiment
model
shown
upregul
ang
phase
clinic
trial
progress
phase
ii
test
placebocontrol
trial
administr
broad
rang
dose
drug
patient
ard
result
rapid
decreas
angii
upregul
ang
without
signific
haemodynam
effect
preliminari
nonsignific
also
evid
suggest
decreas
level
indic
intervent
worth
pursu
futur
treatment
ard
multipl
compon
ra
implic
directli
indirectli
pathogenesi
vili
ard
grow
evid
axi
promot
injuri
fibrosi
play
domin
role
pathogenesi
vili
ard
masr
axi
exert
antiinflammatori
antifibrot
effect
given
lack
effect
pharmacolog
treatment
ard
pathophysiolog
role
ra
vili
ard
area
warrant
investig
quit
common
tabl
summari
evid
reninangiotensin
system
ra
pharmacolog
agent
prevent
acut
respiratori
distress
syndrom
ard
ventilatorinduc
lung
injuri
vili
mani
pharmacolog
candid
ard
shown
less
effect
despit
identif
potenti
promis
candid
preclin
studi
particular
multipl
ra
compon
experiment
assess
two
target
relat
compound
shown
promi
progress
evalu
clinic
trial
discrep
result
clinic
trial
preclin
research
frequent
mention
reason
heterogen
ard
studi
clearli
shown
heterogen
ard
variabl
ace
activ
potenti
effect
outcom
ard
patient
importantli
sinc
ard
sort
highlyheterogen
diseas
subgroup
analysi
base
two
biolog
phenotyp
indic
differ
respons
treatment
increasingli
consid
highli
applic
evalu
treatment
respons
similarli
ace
id
genotyp
offer
possibl
predict
risk
ard
occurr
thu
consider
emphasi
biolog
phenotyp
ard
ace
id
genotyp
open
perspect
precis
medicin
target
therapi
ard
experiment
limit
number
clinic
trial
shown
ra
promis
therapeut
target
larg
scale
welldesign
clinic
trial
parallel
mechanist
studi
requir
determin
whether
treatment
benefit
critic
ill
patient
see
tabl
none
